Left ventricular hypertrophy in essential hypertension: current aspects of pathogenesis, diagnosis and treatment

Left ventricular hypertrophy (LVH) is associated with unfavorable cardiovascular risk profile. LVH raises The risk of coronary heart disease in more than twice, stroke - three times more, heart failure - nearly 8 times more. According to our observational data (1916 patients with essential hypertension) 23% subjects had concentric LVH, 19% - eccentric LVH, 11% - concentric LV remodeling, 47% - normal LV geometry. Under additional analysis of 5714 cards of hypertensive patients, 0,91% of them had asymmetric LVH. In comparison with eccentric LVH persons, subjects with concentric LVH had higher systolic and diastolic blood pressure (p2) was accompanied by marked decrease of left ventricular mass, overnight blood pressure levels and also by significant reduction of neurohumoral regulatory pattern.

essential hypertension , left ventricular hypertrophy , left ventricular geometry , renin-angiotensin-aldosterone system

1. Kannel W. B. Left ventricular hypertrophy as a risk factor in arterial hypertension // Eur. Heart J. - 1992. - Vol. 13. - P. 82-88.

2.

3. Verdecchia P. Controlling blood pressure in patients with left ventricular hypertrophy // Renin Angiotensin System Cardiovasc. Med. - 2006. - Vol. 2, № 3. - P. 2-5.

4.

5. Tsioufis C., Vezali E., Tsiachris D. et al. Left ventricular hypertrophy versus chronic kidney disease as predictors of cardiovascular events in hypertension: a Greek 6-year-follow-up study. Original papers // Epidemiology. - 2009. - Vol. 27, № 4. - P. 744-752.

6.

7. Bagaeva Z., Barsukov A., Tchernyshov V. et al. Some anamnestic peculiarities in essential hypertensive patients with different types of left ventricle hypertrophy // J. Hypertens. - 2008. - Vol. 26 (Suppl. 1). - P. S423.

8.

9. Barsukov A., Shoustov S., Resvantzev M. et al. Asymmetrical left ventricle hypertrophy in essential hypertension: echocardiographic data // J. Hypertens. - 2007. - Vol. 25 (suppl. 2). - P. S99.

10.

11. Barsukov A., Bagaeva Z., Kizishin V. et al. Concentric and excentric left ventricle hypertrophy in essential hypertension: Echocardiographic data // J. Hypertens. - 2008. - Vol. 26 (suppl. 1). - P. 414.

12.

13. Барсуков А.В., Пронина Е.В., Резванцев М.В. Особенности структурно-функционального ремоделирования сердца и нейрогуморальной регуляции кровообращения у пациентов с эссенциальной артериальной гипертензией, имеющих асимметричную гипертрофию левого желудочка // Вестник Российской Военно-медицинской академии. - 2007. - T. 2. - C. 14-17.

14.

15. Barsukov A., Bagaeva Z., Rezvantsev M. et al. Some aspects of problem of left ventricular mass appropriation in overweight essential hypertensive patients // J. Hypertens. - 2009. - Vol. 27 (Suppl. 4). - P. 206.

16.

17. Zanchetti A., Cuspidi C., Comarella L. et al. Left ventricular diastolic dysfunction in elderly hypertensives: results of the APROS-study // J. Hypertens. - 2007. - Vol. 25, № 10. - P. 2158-2167.

18.

19. Барсуков А.В., Багаева З.В., Кадин Д.В. и др. Минералокортикоидный эксцесс и гипертрофия левого желудочка // Артериальная гипертензия. - 2008. - T. 14, № 3. - C. 211-219.

20.

21. Carey R.M. Primary aldosteronism // Horm. Res. - 2009. - Vol. 71 (Suppl 1). - P. 8-12.

22.

23. Schmieder R., Martus P., Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: meta-analysis of randomized studies // JAMA - 1996. - Vol. 275, № 9. - P. 1507-1513.

24.

25. Klingbeil A.U., Schneider M., Martus P. et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension // Am. J. Med. - 2003. - Vol. 115, № 1. - P. 41-46.

26.

27. Yusuf S. and TRANSCEND investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial // Lancet. - 2008. - Vol. 372, № 9644. -: P. 1174-1183.

28.

29. Yusuf S., Teo K.K., Pogue J. et al. The ONTARGET Investigators. Telmisartan, ramipril or both in patients at high risk for vascular events // N. Engl. J. Med. - 2008. - Vol. 358. - P. 1547-1559.

30.

31. Franz I.W., Tonnesmann U., Muller J.F. Time course of complete normalization of left ventricular hypertrophy during long-term antihypertensive therapy with angiotensin converting enzyme inhibitors // Am. J. Hypertens. - 1998. - Vol. 11. - P. 631-639.

32.

33. Барсуков А.В., Пронина Е.В., Шустов С.Б. К вопросу о патогенезе и лечении асимметричной гипертрофии левого желудочка при эссенциальной гипертензии // Артериальная гипертензия. - 2008. - T. 14, № 4. - С. 360-369

34.

35. Dahlof B., Devereux R., Kjeldsen S. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized study against atenolol // Lancet. - 2002. - Vol. 359. - P. 995-1003.